A Phase 1/2 interventional study of IVT Aflibercept and SC CLS-TA in Diabetic Macular Edema, sponsored by Clearside Biomedical, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-13.
Sponsored by Clearside Biomedical, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,022 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 389 under way, 12 of them phase 3. Diabetes Mellitus · United States.
Among the 3,022 studies in Diabetes Mellitus with a site in United States, this one is the 2,023rd largest by enrollment of the 2,501 interventional ones that give a count, is one of 125 that started in 2016, is one of 58 in phase 1/2, and was the 1,973rd registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →289 of the 3,022 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
Wayne State University · Sites in United States
Ages 16–20
Mayo Clinic · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,022 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 262 · Phase 2 371 · Phase 3 340 · Phase 4 215
First in 1976; this study’s year is marked. 125 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 82 across the 2,501 interventional studies, 159 across the 499 observational. Of the 2,397 that completed or were terminated, 990 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
852 of 3,022 have an industry lead sponsor. The 10 most frequent:
Clearside Biomedical, Inc. is the lead sponsor of 14 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Clearside Biomedical, Inc. has 2 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
139 of the studies in Diabetes Mellitus with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03982693Phase 3Mt. Sinai Medical Center, MiamiTrial to Assess Chelation Therapy in Critical Limb Ischemia | 2026-12 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07556354University of Alabama at BirminghamEmpowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City | 2026-11 |
Add all 139 to your calendar (.ics) → With an account.
Among the 3,022 studies in Diabetes Mellitus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to demonstrate the safety and tolerability of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema associated with diabetes mellitus.
This is a Phase 1/2, multicenter, open-label study in subject with DME associated with diabetes mellitus.
Subjects will be screened and if eligible, will be assigned to study arm at the Baseline Visit (Visit 1, Day 0).
Following the Baseline Visit, subjects will participate in six monthly follow-up visits (Visit 2-7; Weeks 4-24) for safety and efficacy assessments and to determine whether additional therapy is needed based upon pre-defined criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment in the TX Naive arm will consist of one unilateral injection of IVT aflibercept in combination with one unilateral injection of SC CLS-TA in the same eye.
Drug: IVT Aflibercept · Drug: SC CLS-TA
Treatment in the Previous TX arm of the study will consist of one unilateral injection of SC CLS-TA.
Drug: SC CLS-TA
IVT aflibercept \[2 mg (50 µL)\]
Also known as: Aflibercept
\[4 mg (100 µL)\]
Also known as: Triamcinolone Acetonide
Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events
Number of participants with treatment emergent adverse events and serious adverse events reported over 6 months of follow-up
Time frame: Over 6 months of follow-up
Mean Change From Baseline in Intraocular Pressure
Baseline and change from baseline at 6 months in intraocular pressure as measured by applanation tonometry
Time frame: Baseline and 6 months
Mean Change From Baseline in Central Subfield Thickness
Baseline and change from baseline at 6 months in central subfield thickness. Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.
Time frame: Baseline and 6 months
Best Corrected Visual Acuity
Baseline and Change from baseline at 6 months in best corrected visual acuity before and after treatment Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured as the number of letters read correctly on an ETDRS eye chart. A positive change from baseline value represents an improvement in vision.
Time frame: Baseline and 6 months
CLS-TA Injections
After the initial treatment with CLS-TA, with or without intravitreal aflibercept, at Baseline, retreatment with CLS-TA was allowed in either treatment group from Month 2 through Month 6 if pre-defined retreatment criteria were met. Number of patients receiving 0, 1, 2, 3, 4 or 5 retreatments with CLS-TA.
Time frame: 2 to 6 months following initial treatment with study drug
| Milestone | TX Naïve Arm | Previous TX Arm |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 9 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Number of participants with treatment emergent adverse events and serious adverse events reported over 6 months of follow-up
| Participants | TX Naïve Arm | Previous TX Arm |
|---|---|---|
| Number of participants with treatment emergent adverse events | 8 | 9 |
| Number of participants with serious adverse events | 0 | 0 |
Baseline and change from baseline at 6 months in intraocular pressure as measured by applanation tonometry
| mm Hg | TX Naïve Arm | Previous TX Arm |
|---|---|---|
| Baseline | 14.2 ± 3.52 | 13.3 ± 2.50 |
| Month 6 | -0.3 ± 2.41 | 2.8 ± 7.89 |
Baseline and change from baseline at 6 months in central subfield thickness. Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.
| Microns | Previous TX Arm | TX Naïve Arm |
|---|---|---|
| Baseline | 421.6 ± 94.33 | 472.7 ± 109.46 |
| Month 6 | -90.9 ± 62.48 | -119.6 ± 65.48 |
Baseline and Change from baseline at 6 months in best corrected visual acuity before and after treatment Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured as the number of letters read correctly on an ETDRS eye chart. A positive change from baseline value represents an improvement in vision.
| Letters | TX Naïve Arm | Previous TX Arm |
|---|---|---|
| Baseline | 67.2 ± 11.66 | 67.2 ± 8.95 |
| Month 6 | 8.5 ± 11.96 | 1.1 ± 11.94 |
After the initial treatment with CLS-TA, with or without intravitreal aflibercept, at Baseline, retreatment with CLS-TA was allowed in either treatment group from Month 2 through Month 6 if pre-defined retreatment criteria were met. Number of patients receiving 0, 1, 2, 3, 4 or 5 retreatments with CLS-TA.
| Participants | TX Naïve Arm | Previous TX Arm |
|---|---|---|
| 0 additional injections | 4 | 1 |
| 1 additional injection | 2 | 3 |
| 2 additional injections | 0 | 2 |
| 3 additional injections | 2 | 0 |
| 4 additional injections | 2 | 4 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TX Naïve Arm | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Previous TX Arm | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Event | TX Naïve Arm | Previous TX Arm |
|---|---|---|
| CataractEye disorders | 3/10 | 2/10 |
| Conjunctival haemorrhageEye disorders | 3/10 | 2/10 |
| CataractEye disorders | 2/10 | 0/10 |
| HeadacheNervous system disorders | 1/10 | 2/10 |
| Dry eyeEye disorders | 0/10 | 1/10 |
| Dry eyeEye disorders | 0/10 | 1/10 |
| EpiscleritisEye disorders | 0/10 | 1/10 |
| Eye irritationEye disorders | 1/10 | 0/10 |
| Eye irritationEye disorders | 1/10 | 0/10 |
| Eye painEye disorders | 0/10 | 1/10 |
The Intent-to-treat population included all subjects who received study treatment.
| Age, Categorical(Participants) | TX Naïve Arm | Previous TX Arm | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 6 | 11 |
| >=65 years | 5 | 4 | 9 |
| Age, Continuous(Years) | TX Naïve Arm | Previous TX Arm | Total |
|---|---|---|---|
| Mean | 61.9 ± 7.28 | 63.1 ± 8.31 | 62.5 ± 7.63 |
| Sex: Female, Male(Participants) | TX Naïve Arm | Previous TX Arm | Total |
|---|---|---|---|
| Female | 4 | 4 | 8 |
| Male | 6 | 6 | 12 |
| Race (NIH/OMB)(Participants) | TX Naïve Arm | Previous TX Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 6 | 6 | 12 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | TX Naïve Arm | Previous TX Arm | Total |
|---|---|---|---|
| United States | 10 | 10 | 20 |
| Baseline Best Corrected Visual Acuity(Letters) | TX Naïve Arm | Previous TX Arm | Total |
|---|---|---|---|
| Mean | 67.2 ± 11.66 | 67.2 ± 8.95 | 67.2 ± 10.12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2016 to primary completion in Oct 2017, 11 months.
Results were first posted in Apr 2021, 3 years 6 months after primary completion. A results delay was requested in May 2018.
Of 40 phase 1/2 interventional studies under Diabetes Mellitus, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triamcinolone Acetonide
Clearside Biomedical, Inc.